Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Using the AbiprotTM antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Vinnova
Deal Size : $0.5 million
Deal Type : Funding
Details : AbiprotTM can identify high-affinity antibody binding sites in any given protein with single amino acid resolution while the protein resides in its native environment.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Vinnova
Deal Size : $0.5 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Medivir
Deal Size : Undisclosed
Deal Type : Partnership
Medivir and SciLifeLab Partner to Identify Covid-19 Drug Candidates
Details : The aim of the collaboration is to find potential inhibitors of the main protease of SARS CoV-2, an essential non-structural protein, Mpro, required for virus replication.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Medivir
Deal Size : Undisclosed
Deal Type : Partnership